On July 28, 2026, GSK PLC GSK shares rose 3.3% to a current price of $53.71. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $61.70 and a low of $36.75.
- GF Value™ verdict indicates that GSK is currently priced at $53.71, which is 21.1% above its estimated fair value of $44.37.
- GSK has a GF Score™ of 69/100, suggesting it is above average when evaluated against various financial metrics.
- The most notable signal is the insider activity, with no transactions recorded in the last three months.
Is GSK Overvalued or Undervalued?
According to the GF Value™, GSK is considered modestly overvalued, with its current share price of $53.71 significantly exceeding the intrinsic value estimate of $44.37. This represents a potential downside of 21.1% if the market corrects towards the GF Value™. The GF Value™ is derived from historical trading multiples, past business growth, and future performance estimates, providing an insight into the stock's true worth. As GSK’s shares have appreciated considerably over the past year, the risk of a price correction increases, particularly in the context of its current overvaluation.
Investors should be cautious given this valuation context, as purchasing shares at an elevated price may limit future upside potential. The margin of safety appears tight, suggesting that while GSK may offer some growth prospects, the current pricing does not reflect an attractive entry point based on intrinsic value estimates.
How Does GSK's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E (TTM) | 14.0x | 13.9x (5-Year Median) |
| Forward P/E | 11.4x | - |
The current P/E ratio of GSK at 14.0x is slightly above its 5-year median of 13.9x, while the forward P/E of 11.4x indicates analysts’ expectations for earnings growth in the near future. This P/E analysis aligns with the GF Value™ verdict of being overvalued, as the historical valuation metrics suggest that the stock is trading at a premium compared to its past performance.
What Does GSK's GF Score™ Tell Us?
The GF Score™ is a comprehensive measure that evaluates a company’s financial strength, profitability, growth potential, valuation, and momentum based on various key performance indicators. GSK's GF Score™ of 69/100 indicates a solid standing, with the strongest sub-rank being profitability at 8/10, while momentum lags at 1/10.
| Metric | Rating |
|---|---|
| GF Score™ | 69/100 |
| Financial Strength | 5/10 |
| Profitability | 8/10 |
| Growth | 6/10 |
| Valuation | 6/10 |
| Momentum | 1/10 |
GSK's profitability score of 8/10 highlights its strong ability to generate profits, while the financial strength score of 5/10 indicates a moderate level of financial stability. However, the low momentum rank of 1/10 suggests weak current performance trends, which may be a factor contributing to the stock's overvaluation based on GF Value™ metrics.
What Are Gurus and Insiders Doing with GSK?
Currently, 16 gurus hold positions in GSK, with 4 adding to their stakes and 13 trimming their positions over recent quarters. This mixed activity reflects varied sentiment among seasoned investors regarding GSK's growth potential and current valuation.
Despite the lack of insider trading activity in the last three months, the significant number of gurus altering their positions indicates a cautious approach towards GSK. The trimming of positions could suggest some concerns regarding the stock’s current valuation, aligning with the findings of its overvaluation based on GF Value™.
What This Means for Investors
Based on the GF Value™ analysis, GSK is currently overvalued. The stock's price significantly exceeds its intrinsic value estimate, which raises concerns about future price corrections and limits the attractiveness of its dividend yield relative to its payout ratio and growth potential. Therefore, while GSK has shown strong profitability and a decent GF Score™, the elevated price presents a risk for potential investors. For an in-depth look at GSK PLC GSK, visit the GSK PLC (GSK) stock page.
Frequently Asked Questions
What is GSK's GF Score™?
GSK's GF Score™ stands at 69/100, indicating an above-average evaluation across various financial metrics, suggesting a solid business performance overall.
Is GSK overvalued or undervalued?
GSK is currently considered overvalued, with a GF Value™ estimate of $44.37 indicating a significant premium over its current price of $53.71.
What is GSK's P/E ratio?
GSK has a P/E ratio of 14.0x TTM, which is slightly above its historical 5-year median of 13.9x, confirming its overvaluation relative to historical performance.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
